All Stories

  1. MRI susceptibility map weighted imaging (SMWI) as a neurodegeneration biomarker in the prodromal to overt alpha-synucleinopathy continuum
  2. Smartphone-based prediction of dopaminergic deficit in prodromal and manifest Parkinson’s disease
  3. Cerebrospinal fluid NPTX2 and [18F]FDG PET track serotonergic vulnerability to neurodegeneration in prodromal Alzheimer’s disease
  4. Uncovering Clinical and Functional Neuroimaging Characteristics of Overt Stage Phenotypes Within the α-Synucleinopathy Spectrum
  5. Cerebrospinal Fluid Biomarkers Profiling in Cerebral Amyloid Angiopathy and Relationship With Disease Phenotypes
  6. Clinical Pathways for Diagnosing Neurocognitive Disorders: Insights From Process Mining a Memory Clinic Cohort
  7. Rituximab retreatment guided by CD27+ B-cell count vs. clinical relapse in anti-MAG polyneuropathy: a cost-effective approach with lower cumulative doses
  8. Longitudinal changes in [18F]FDG PET brain metabolism as a prognostic marker in autoimmune encephalitis
  9. [18F]FDG PET metabolic correlates of cerebrospinal fluid TAR DNA-binding protein 43 in prodromal Alzheimer's disease
  10. The compensatory effect of education as revealed by resting-state electroencephalographic alpha rhythms in patients with dementia due to Parkinson’s disease: findings from an exploratory study
  11. Neuropsychological and clinical variables associated with cognitive trajectories in patients with Alzheimer's disease
  12. Clinical and metabolic profiles in behavioural frontotemporal dementia: Impact of age at onset
  13. The Many Faces of REM Sleep Behavior Disorder. Providing Evidence for a New Lexicon
  14. Abnormal electroencephalographic rhythms from quiet wakefulness to light sleep in Alzheimer’s disease patients with mild cognitive impairment
  15. Resting-state electroencephalographic rhythms depend on sex in patients with dementia due to Parkinson's and Lewy Body diseases: An exploratory study
  16. Magnetic susceptibility components reveal different aspects of neurodegeneration in alpha-synucleinopathies
  17. Resting-State EEG Alpha Rhythms Are Related to CSF Tau Biomarkers in Prodromal Alzheimer’s Disease
  18. CSF IL-6, GDF-15, GFAP and NfL levels in early Alzheimer disease: a pilot study
  19. Role of Blood P-Tau Isoforms (181, 217, 231) in Predicting Conversion from MCI to Dementia Due to Alzheimer’s Disease: A Review and Meta-Analysis
  20. Clinical and biological underpinnings of longitudinal atrophy pattern progression in Alzheimer's disease
  21. Investigating interleukin-8 in Alzheimer's disease: A comprehensive review
  22. Relationship between Posterior Resting-State Electroencephalographic Alpha Rhythms and Cerebrospinal Fluid Biomarkers of Neuropathology in Patients with Alzheimer’s Disease Mild Cognitive Impairment
  23. Progression trajectories from prodromal to overt synucleinopathies: a longitudinal, multicentric brain [18F]FDG-PET study
  24. Anti-LGI1 encephalitis and Langerhans cell histiocytosis: Two associated entities? A case report
  25. Toward Quantitative Neurology: Sensors to Assess Motor Deficits in Dementia
  26. FDG-PET and ASL MRI identify largely overlapping hypermetabolic and hyperperfusion changes in limbic autoimmune encephalitis
  27. Metabolic and dopaminergic correlates of intellectual enrichment in de-novo Parkinson's disease patients
  28. Limbic Network Derangement Mediates Unawareness of Apathy in Mild Cognitive Impairment due to Alzheimer’s Disease: Clues from [18F]FDG PET Voxel-Wise Analysis
  29. Clinical versus biomarker-based diagnosis of neurocognitive disorders – Authors' reply
  30. Clinical and diagnostic implications of Alzheimer’s disease copathology in Lewy body disease
  31. Resting state electroencephalographic alpha rhythms are sensitive to Alzheimer’s disease mild cognitive impairment progression at a 6-month follow-up
  32. Ma2 antibody‐associated limbic encephalitis: The early etiology treatment may modify the disease clinical trajectory
  33. Autoimmune encephalitis: what the radiologist needs to know
  34. Diagnostic and prognostic value of dual-point amyloid PET in Alzheimer’s disease (AD) mimickers
  35. Presynaptic Dopaminergic Imaging Characterizes Patients with REM Sleep Behavior Disorder Due to Synucleinopathy
  36. European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders
  37. Diagnostic performance of molecular imaging methods in predicting the progression from mild cognitive impairment to dementia: an updated systematic review
  38. Tracking the progression of Alzheimer's disease: Insights from metabolic patterns of SOMI stages
  39. Incident anti-LGI1 autoimmune encephalitis during dementia with Lewy bodies: when Occam razor is a double-edged sword
  40. Alzheimer’s disease (AD) co-pathology in dementia with Lewy bodies (DLB): implications in the disease modification era
  41. COVID-19-associated serum and cerebrospinal fluid cytokines in post- versus para-infectious SARS-CoV-2-related Guillain–Barré syndrome
  42. Cerebrospinal fluid NPTX2 changes and relationship with regional brain metabolism metrics across mild cognitive impairment due to Alzheimer's disease
  43. Sex differences in brain atrophy in dementia with Lewy bodies
  44. Relationship between default mode network and resting-state electroencephalographic alpha rhythms in cognitively unimpaired seniors and patients with dementia due to Alzheimer’s disease
  45. Editorial: CSF and blood biomarkers in COVID-19 and other neuroinfectious diseases
  46. CSF Synaptic Biomarkers in AT(N)-Based Subgroups of Lewy Body Disease
  47. Validation of the REM behaviour disorder phenoconversion-related pattern in an independent cohort
  48. Discrepancy Between Patient and Caregiver Estimate of Apathy Predicts Dementia in Patients with Amnestic Mild Cognitive Impairment
  49. Right posterior hypometabolism in Pisa syndrome of Parkinson’s disease: A key to explain body schema perception deficit?
  50. Different z-score cut-offs for striatal binding ratio (SBR) of DaT SPECT are needed to support the diagnosis of Parkinson’s Disease (PD) and dementia with Lewy bodies (DLB)
  51. Compressed sensing (CS) MP2RAGE versus standard MPRAGE: A comparison of derived brain volume measurements
  52. Cognitive and Brain Metabolism Profiles of Mild Cognitive Impairment in Prodromal Alpha-Synucleinopathy
  53. European consensus for the diagnosis of MCI and mild dementia: Preparatory phase
  54. Derivation and Validation of a Phenoconversion‐Related Pattern in Idiopathic Rapid Eye Movement Behavior Disorder
  55. A case of Huntington disease‐like 2 in a patient of African ancestry: the everlasting support of clinical examination in the molecular era
  56. The Role of Monoaminergic Tones and Brain Metabolism in Cognition in De Novo Parkinson’s Disease
  57. Intravenous immunoglobulin bridging to rituximab in NMDAR encephalitis patients non-responders to first-line treatments
  58. Cerebrospinal fluid β-synuclein as a synaptic biomarker for preclinical Alzheimer’s disease
  59. Epileptic phenotypes in autoimmune encephalitis: from acute symptomatic seizures to autoimmune-associated epilepsy
  60. Case Report: Post-COVID-19 Vaccine Recurrence of Guillain–Barré Syndrome Following an Antecedent Parainfectious COVID-19–Related GBS
  61. Specific Cerebrospinal Fluid SerpinA1 Isoform Pattern in Alzheimer’s Disease
  62. Neurological long-COVID in the outpatient clinic: Two subtypes, two courses
  63. The Free and Cued Selective Reminding Test: Discriminative Values in a Naturalistic Cohort
  64. Exploring the brain metabolic correlates of process-specific CSF biomarkers in patients with MCI due to Alzheimer's disease: preliminary data
  65. The Role of Hub and Spoke Regions in Theory of Mind in Early Alzheimer’s Disease and Frontotemporal Dementia
  66. Case 4: Parkinson’s Disease with Onset as Mild Cognitive Impairment (MCI)
  67. Added value of semiquantitative analysis of brain FDG-PET for the differentiation between MCI-Lewy bodies and MCI due to Alzheimer’s disease
  68. Polysomnographic correlates of sleep disturbances in de novo, drug naïve Parkinson’s Disease
  69. Stratification Tools for Disease‐Modifying Trials in Prodromal Synucleinopathy
  70. Abnormal sweating and “skin flushing” as possible predictive factor for treatment related fluctuations in Guillain-Barré syndrome: a case series and a review of the literature
  71. Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration
  72. A case series of parainfectious Guillain-Barré syndrome linked to influenza A (H1N1) virus infection
  73. Dopaminergic and Serotonergic Degeneration and Cortical [ 18 F ]Fluorodeoxyglucose Positron Emission Tomography in De Novo Parkinson's Disease
  74. Brain Metabolic Correlates of Persistent Olfactory Dysfunction after SARS-Cov2 Infection
  75. FDG PET Unveils the Course of Paraneoplastic Cerebellar Degeneration
  76. Cuneus/precuneus as a central hub for brain functional connectivity of mild cognitive impairment in idiopathic REM sleep behavior patients
  77. Brain Resources: How Semantic Cueing Works in Mild Cognitive Impairment due to Alzheimer’s Disease (MCI-AD)
  78. Sex differences in neuroimaging biomarkers in healthy subjects and dementia
  79. Rapid eye movement sleep behavior disorder: A proof‐of‐concept neuroprotection study for prodromal synucleinopathies
  80. Striatal dopamine transporter SPECT quantification: head-to-head comparison between two three-dimensional automatic tools
  81. Neuroimaging Findings in Mild Cognitive Impairment
  82. Anatomical and neurochemical bases of theory of mind in de novo Parkinson's Disease
  83. The role of anterior prefrontal cortex in prospective memory: an exploratory FDG-PET study in early Alzheimer's disease
  84. Utility of quantitative EEG in early Lewy body disease
  85. Bendamustine–rituximab (BR) combined therapy for treatment of immuno-mediated neuropathies associated with hematologic malignancy
  86. Brain Aging, Cardiovascular Diseases, Mixed Dementia, and Frailty in the Oldest Old: From Brain Phenotype to Clinical Expression
  87. Subgroup comparison according to clinical phenotype and serostatus in autoimmune encephalitis: a multicenter retrospective study
  88. Epilepsy in Neurodegenerative Dementias: A Clinical, Epidemiological, and EEG Study
  89. The fate of patients with REM sleep behavior disorder and mild cognitive impairment
  90. Clinical and MRI Predictors of Conversion From Mild Behavioural Impairment to Dementia
  91. Outcomes after single-cycle rituximab monotherapy in patients with anti-MAG polyneuropathy: A bi-center experience with an average follow-up of 11 years
  92. Reciprocal Incremental Value of 18F-FDG-PET and Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment Patients Suspected for Alzheimer’s Disease and Inconclusive First Biomarker
  93. Importance of intensive and prolonged rehabilitative treatment on the Guillain-Barrè syndrome long-term outcome: a retrospective study
  94. Serum neurofilament light chain rate of change in Alzheimer’s disease: potentials applications and notes of caution
  95. Could arterial spin labelling perfusion imaging uncover the invisible in N ‐methyl‐ d ‐aspartate receptor encephalitis?
  96. Neuroimaging findings and clinical trajectories of Lewy body disease in patients with MCI
  97. Head-to-Head Comparison among Semi-Quantification Tools of Brain FDG-PET to Aid the Diagnosis of Prodromal Alzheimer’s Disease
  98. 18F-FDG-PET/CT (FDG-PET) in Neurodegenerative Disease
  99. Increased incidence of axonal Guillain‐Barré syndrome in La Spezia area of Italy: A 13‐year follow‐up study
  100. N-methyl-d-aspartate receptor antibody-related pathologies and pre-existent mental state disorders
  101. Accuracy and generalization capability of an automatic method for the detection of typical brain hypometabolism in prodromal Alzheimer disease
  102. Getting the high school diploma with only one hemisphere: a case report
  103. Metabolic correlates of reserve and resilience in MCI due to Alzheimer's Disease (AD)
  104. Spinocerebellar ataxia 17: full phenotype in a 41 CAG/CAA repeats carrier
  105. Machine Learning Based Analysis of FDG-PET Image Data for the Diagnosis of Neurodegenerative Diseases
  106. Prediction of cognitive worsening in de novo Parkinson's disease: Clinical use of biomarkers
  107. Clinical utility and research frontiers of neuroimaging in movement disorders